- cafead   Sep 19, 2022 at 09:12: AM
via As Theravance Biopharma tries to plot its comeback, it announced Monday morning that it would be buying its own shares from GSK — one of its major shareholders.
Theravance is buying back over 9.5 million shares from GSK for roughly $94 million, according to an SEC filing. In addition, Theravance plans to buy back $95 million from its existing investors “in the near term,” and another $60 million in its shares on the open market. In a press release, Theravance says it hopes to complete that part of its plan by the end of 2023.
article source
Theravance is buying back over 9.5 million shares from GSK for roughly $94 million, according to an SEC filing. In addition, Theravance plans to buy back $95 million from its existing investors “in the near term,” and another $60 million in its shares on the open market. In a press release, Theravance says it hopes to complete that part of its plan by the end of 2023.
article source